GSK的Berpirovirsen在日本获得SENKU的指定,加速药物研制和批准。 GSK's bepirovirsen receives SENKU designation in Japan, accelerating drug development and approval.
GSK的Berpirovirsen得到日本卫生、劳动和福利部指定的SENKU。 GSK's bepirovirsen receives SENKU designation from Japan's Ministry of Health, Labour and Welfare. 这一指定表明该药物有可能治疗棘手疾病。 The designation signifies the potential for the drug to treat intractable diseases. 该指定将加快日本药物的研制和批准过程。 The designation will accelerate the drug's development and approval process in Japan.